These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 23535934)

  • 21. Thymoquinone in autoimmune diseases: Therapeutic potential and molecular mechanisms.
    Ali MY; Akter Z; Mei Z; Zheng M; Tania M; Khan MA
    Biomed Pharmacother; 2021 Feb; 134():111157. PubMed ID: 33370631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunomodulatory drugs: oral and systemic adverse effects.
    Bascones-Martinez A; Mattila R; Gomez-Font R; Meurman JH
    Med Oral Patol Oral Cir Bucal; 2014 Jan; 19(1):e24-31. PubMed ID: 23986016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Immunoglobulins and physiopathology: actual indications].
    Mouthon L; Guilpain P
    Rev Med Interne; 2007 May; 28 Spec No. 1():11-7. PubMed ID: 17768833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spurs in the hunt for new immunomodulatory drug targets.
    Ward SG; O'Neill LA
    Curr Opin Pharmacol; 2012 Aug; 12(4):439-43. PubMed ID: 22770734
    [No Abstract]   [Full Text] [Related]  

  • 25. Harnessing Immunomodulatory Polymers for Treatment of Autoimmunity, Allergy, and Transplant Rejection.
    Tu AB; Krishna G; Smith KR; Lewis JS
    Annu Rev Biomed Eng; 2024 Jul; 26(1):415-440. PubMed ID: 38959388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug delivery technologies for autoimmune disease.
    Phillips BE; Giannoukakis N
    Expert Opin Drug Deliv; 2010 Nov; 7(11):1279-89. PubMed ID: 20958218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Managing patients with side effects and adverse events to immunoglobulin therapy.
    Azizi G; Abolhassani H; Asgardoon MH; Shaghaghi S; Negahdari B; Mohammadi J; Rezaei N; Aghamohammadi A
    Expert Rev Clin Pharmacol; 2016; 9(1):91-102. PubMed ID: 26496172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ibrutinib-A double-edge sword in cancer and autoimmune disorders.
    Kokhaei P; Jadidi-Niaragh F; Sotoodeh Jahromi A; Osterborg A; Mellstedt H; Hojjat-Farsangi M
    J Drug Target; 2016; 24(5):373-85. PubMed ID: 26362595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rituximab therapy for autoimmune haematological diseases.
    Barcellini W; Zanella A
    Eur J Intern Med; 2011 Jun; 22(3):220-9. PubMed ID: 21570637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immunomodulation therapy for autoimmune diseases. New hope for patients with autoimmune diseases].
    Szegedi G
    Orv Hetil; 2005 Apr; 146(14):635-43. PubMed ID: 15889537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Immunotherapy with immune checkpoint inhibitors and hepatitis].
    Baudoux N; Berthod G; Bally F; Renard P; Anchisi S
    Rev Med Suisse; 2019 May; 15(651):1017-1021. PubMed ID: 31091035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions.
    Vugmeyster Y; Harrold J; Xu X
    AAPS J; 2012 Dec; 14(4):714-27. PubMed ID: 22798020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An antibody treats almost all refractory autoimmune diseases: fact and beyond.
    Lin LY; Hsu MH; Yang KD
    J Formos Med Assoc; 2012 Apr; 111(4):181-2. PubMed ID: 22655322
    [No Abstract]   [Full Text] [Related]  

  • 34. Peptide-directed liposomal delivery improves the therapeutic index of an immunomodulatory cytokine in controlling autoimmune arthritis.
    Meka RR; Venkatesha SH; Moudgil KD
    J Control Release; 2018 Sep; 286():279-288. PubMed ID: 30081142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Monoclonal antibodies. Principles, generation, application, and side effects].
    Sack U; Emmrich F
    Internist (Berl); 2008 Aug; 49(8):919-20, 921-4, 926-8. PubMed ID: 18587546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging small molecule and biological therapeutic approaches for the treatment of autoimmunity.
    Leishman AJ; Sims GP; Sleeman M; Braddock M
    Expert Opin Investig Drugs; 2011 Jan; 20(1):23-39. PubMed ID: 21118058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T cell factor 1: A master regulator of the T cell response in disease.
    Escobar G; Mangani D; Anderson AC
    Sci Immunol; 2020 Nov; 5(53):. PubMed ID: 33158974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis.
    Aktas O; Kieseier B; Hartung HP
    Trends Neurosci; 2010 Mar; 33(3):140-52. PubMed ID: 20045200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review of thalidomide use in the pediatric population.
    Yang CS; Kim C; Antaya RJ
    J Am Acad Dermatol; 2015 Apr; 72(4):703-11. PubMed ID: 25617013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators.
    Juif PE; Kraehenbuehl S; Dingemanse J
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):879-95. PubMed ID: 27249325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.